Current concepts in secondary prevention after acute myocardial infarction

Herz

Volumn 25, Issue 1, 2000, Pages 47-60

  Mehta, Rajendra H ^a   Bossone, Eduardo ^b   Eagle, Kim A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

Cardiac rehabilitation; Coronary artery disease; Myocardial infarction; Pharmacologic therapy; Secondary prevention; Smoking

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRILAT; ESTROGEN; GESTAGEN; LISINOPRIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METOPROLOL; NIFEDIPINE; PRAVASTATIN; PROPRANOLOL; RAMIPRIL; SIMVASTATIN; TIMOLOL; TRANDOLAPRIL; VERAPAMIL; ZOFENOPRIL;

ACUTE HEART INFARCTION; ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EXTRASYSTOLE; HEART EJECTION FRACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIFESTYLE; MAJOR CLINICAL STUDY; META ANALYSIS; SECONDARY PREVENTION; SMOKING CESSATION; TREATMENT CONTRAINDICATION;

EID: 0034011216     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03044123     Document Type: Article

References (123)

1. Ambrossioni E, Borghi C, Magnani B. The SMILE Study Investigators. The effect of angiotensin converting enzyme inhibitor zofenopril on mortality and morbidity after acute anterior myocardial infarction. N Engl J Med 1995;332:80-5.
2. American College of Physicians. Guidelines for counseling postmenopausal women about preventive hormone therapy. Ann Intern Med 1992;117:1038-41.
3. American College of Physicians. Health and Public Policy Committee. Cardiac rehabilitation services. J Am Coll Phys 1988;671-3.
4. American Heart Association: Heart and stroke facts. 1995 Statistical Supplement. Dallas: American Heart Association, 1994.
5. Antiplatelet Trialist Collaboration. Collaborative overview of randomized trial of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994;308:81.
6. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J (Clin Res) 1988;296:320-331.
7. Ayanian JZ, Hauptman PJ, Guadagnoti E, et al. Knowledge and practices of generalist and specialist physicians regarding drug therapy for acute myocardial infarction. N Engl J Med 1994; 331: 1136-42.
8. Balsano F, Rizzon P, Violi F, et al. Antiplatelet treatment with ticlopidine in unstable angina: a controlled multicenter trial: the Studio Della Ticlopidina nell'Angina Instabile Group. Circulation 1990;82:17-22.
9. Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 1982;247:1707-14.
10. Bredin D, Loew D, Lechner K, et al. The German-Austrian Aspirin Trial: a comparison of acetyl-salicylic acid, placebo and phencoumon in secondary prevention of myocardial infarction. Circulation 1980;62:63V-72V.
11. Buchwald H, Varco RL, Matts JP, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary artery disease in patients with hypercholesterolemia: report of the program on the Surgical Control of Hypercholesterolemia. N Engl J Med 1990; 323:946-55.
12. Burr ML, Fehily AM, Gilbert JF, et al. Effect of fat, fish, and fiber intakes on death and myocardial reinfarction: Diet Reinfarction Trial (DART). Lancet 1989;757-61.
13. Cairns JA, Conolly SJ, Roberts R, et al. Randomized trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarizations: CAMIAT Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet 1997;349:675-82.
14. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in coronary drug project patients: Long term benefit with niacin. J Am Coll Cardiol 1986;8:1245-55.
15. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996;93:683-8.
16. Case RB, Moss AJ, Case N, et al. Living alone after myocardial infarction: impact on prognosis. JAMA 1992;267:515-9.
17. Chamberlain D. Beta-blockers and calcium antagonists. In: Julian D, Braunwald E, eds. Management of acute myocardial infarction. London: Saunders, 1994:193.
18. Chinese Cardiac Study Collaborative Group. Oral captopril versus placebo among 13634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1) Lancet 1995;345:686-7.
19. Cohen MV, Byrne MJ, Levine B, et al. Low rate of treatment of hypercholesterolemia by cardiologists in patients with suspected and proven coronary artery disease. Circulation 1991;83:1294-304.
20. Col NF, Yarzebski J, Gore JM, et al. Does aspirin consumption affect the presentation or severity of acute myocardial infarction? Arch Intern Med 1995;155:1386.
21. Colditz GA, Hankinso SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589-93.
22. Collaborative overview of randomized trials of antiplatelet therapy II: maintainance of vascular graft of arterial patency by antiplatelet therapy. Br Med J 1994;308:159-68.
23. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-81.
24. Covey LS, Glassman AH. A meta-analysis of double-blinded placebo-controlled trials of clonidine for smoking cessation. Br J Addict 1991;86:991-8.
25. Danish Study Group on Verapamil in Myocardial Infarction. The effect of verapamil on mortality and major events after myocardial infarction: the Danish Verapamil Infarction Trial II (DAVIT II). Am J Cardiol 1990;66:779-85.
26. Danish Study Group on Verapamil in Myocardial Infarction. Verapamil in acute myocardial infarction. Eur Heart J 1984;5:516-28.
27. DeBusk RF, Miller NH, Superko HR, et al. A case-management system for coronary risk factor modification after acute myocardial infarction. Ann Intern Med 1994;120:721-9.
28. Domanski MJ, Hunningbake DB, Compeau L, et al. Post CABG trial: effect of cholesterol lowering and low intensity oral anticoagulation on late saphenous vein graft status. Presented at American College of Cardiology Annual Scientific Session, Orlando, Fla., March 1996.
29. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781-8.
30. Enstrom JE, Kanim LE, Klein MA. Vitamin C intake and mortality among a sample of United States population. Epidemiology 1992; 3:194-202.
31. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993; 269:3015-23.
32. Fletcher GF, Blair SN, Blumenthal J, et al. Statement on exercise: benefits and recommendations for physical activity programs for all Americans. A statement for Health Professionals by the Committee on Exercise and Cardiac Rehabilitation of the Council on Clinical Cardiology, American Heart Association. Circulation 1992: 86:340-4.
33. Frasure-Smith N, Lesperance F, Talajic M. Depression following myocardial infarction: impact on 6-month survival. JAMA 1993; 270:1819-25.
34. Frishman WH, Furberg CD, Friedwald WT. The use of beta-adrenergic blocking drugs in patients with myocardial infarction. Curr Probl Cardiol 1984;9:1-50.
35. Frishman WH, Furberg DC, Freidewald WT. Beta-adrenergic blockade for survivors of acute myocardial infarction. N Engl J Med 1984;310:830-6.
36. Furberg CD. Effect of antiarrhythmic drugs on mortality after acute myocardial infarction. Am J Cardiol 1983;52:32C-6C.
37. Gibson RS, Boden WE, Theroux P, et al. Diltiazem and reinfarction in patients with Non-Q wave myocardial infarction. Results of double-blind, randomized, multicenter trial. N Engl J Med 1986; 315:423-9.
38. GISSI-3. Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6 weeks mortality and ventricular function after acute myocardial infarction: Gruppo Italiano per Io Studio della Sopravvivenza nell'infarto Miocardico. Lancet 1994;343: 1115-22.
39. Goldman L, Sia ST, Cook F, et al. Costs and effectiveness of routine therapy with long term beta-adrenergic antagonists after acute myocardial infarction. N Engl J Med 1988;319:152-7.
40. Goldstein RE, Boccuzzi SJ, Cruess D, et al, the Adverse Experience Committee, and the Multicenter Diltiazem Postinfarction Research Group. Diltiazem increases late onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. Circulation 1991;83:52-60.
41. Goodman SG, Langer A, Durica SS, et al. Safety and anticoagulation effect of a low-dose combination of warfarin and aspirin in clinically stable coronary artery disease. Coumadin Aspirin Reinfarction (CARS) Pilot Study Croup. Am J Cardiol 1994;74:657-61.
42. Gotto AM Jr, LaRosa JC, Hunninghake D, et al. The cholesterol facts: a summary of the evidence relating dietary fats, serum cholesterol, and coronary artery disease: A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. Circulation 1990;81:1721-33.
43. Gourlay SG, McNeil JJ. Anti-smoking products. Med J Aust 1990; 153:699-707.
44. Greco PJ, Eisenberg JM. Changing physician's practices. N Engl J Med 1993;329:1271-3.
45. Haskell WL, Alderman EL, Fair JM, et al. Effect of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP). Circulation 1990;89:975-90.
46. Healy B. Effects of estrogen or estrogen/progestin regimes on heart disease risk factors in post menopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995;273:199-208.
47. Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996;334:1145-9.
48. Herlitz J, Pennert K, Wedel H, et al. Goteborg metoprolol trial: tolerance. Am J Cardiol 1984;53:46D-50D.
49. Herltz J, Blohm M, Hartford M, et al. Delay time in suspected acute myocardial infarction and the importance of its modification. Clin Cardiol 1989;12:370-4.
50. Hines LK, Laird NM, Hewitt P, et al. Meta-analysis of empirical long-term antiarrhythmic therapy after myocardial infarction. JAMA 1989;226:3037-40.
51. Hjalmarson A, Elmfeldt D, Herltz J, et al. Effect on mortality of metoprolol in acute myocardial infarction: a double-blind randomized trial. Lancet 1981;2:823-7.
52. Hjalmarson A, Herlitz J, Holmberg S, et al. The Goteborg metoprolol trial, effects on mortality and morbidity in acute myocardial infarction. Circulation 1983;67:26I-31I.
53. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13.
54. Hurt RD, Sachs DP, Glover ED, et al. A comparison of sustained release bupropion and placebo for smoking cessation. N Engl J Med 1997;337:1195-202.
55. Hypertension Detection and Follow-up Program Cooperative Group. Five year findings of hypertension detection and follow-up program. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA 1979;242:2562-71.
56. ISIS-4. A randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulfate in 58,050 patients with suspected acute myocardial infarction ISIS-4 (4th International Study of Infarct Survival) Collaborative Group. Lancet 1995;345:669-85.
57. ISIS-I (First International Study of Infarct Survival) Collaborative group. Randomized trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction. ISIS-I. Lancet 1986; 2:57-66.
58. Israeli SPRINT Study Group. Secondary Prevention Reinfarction Israeli NifedipineTrial (SPRINT): a randomized intervention trial of nifedipine in patients with acute myocardial infarction. Eur Heart J 1988;9:354-64.
59. Julius DG, Cannon AJ, Frangin G, et al. Randomized trial of effect of amiodarone on mortality in patients with left ventricular dysfunction after recent myocardial infarction: EMIAT European Myocardial Infarct Amiodarone Trial Investigators. Lancet 1997;349: 667-74.
60. Klag MJ, Ford DE, Mead LA, et al. Serum cholesterol in young men and subsequent cardiovascular disease. N Engl J Med 1993;328: 313-8.
61. Krumholz HM, Cohen BJ, Tsevat J, et al. Cost-effectiveness of a smoking cessation program after myocardial infarction. J Am Coll Cardiol 1993;22:1697-702.
62. Kushi LH, Folsom AR, Prineas RJ, et al. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. N Engl J Med 1996;334:1156-62.
63. LaRosa JC. Cholesterol lowering, low cholesterol, and mortality. Am J Cardiol 1993;72:776-86.
64. Leon AS, Certo C, Comoss P, et al. Scientific evidence of the value of cardiac rehabilitation services with emphasis on patients following myocardial infarction. J Cardiopulm Rehabil 1990;10:79-87.
65. Malmberg K. Prospective randomized diabetes study of intensive insulin treatment in long-term survival after acute myocardial infarction in patients with diabetes mellitus. Br Med J 1997;314: 1512-5.
66. May CS, Eberlein KA, Furberg CD, et al. Secondary prevention after myocardial infarction: a review of long term trials. Prog Cardiovasc Dis 1982;24:331-52.
67. Mehta RH, Eagle KA. Secondary prevention in acute myocardial infarction. Br Med J 1998;316:838-42.
68. Meijer A, Vergheught FWA, Werter CJPJ, et al. Aspirin versus coumadin in the prevention of reocclussion and recurrent ischemia after successful thrombolysis: a prospective placebo controlled angiographic study: results of the APRICOT study. Circulation 1993;87:1524-30.
69. MIAMI Trial Research Group. Metoprolol in acute myocardial infarction (MIAMI). A randomized placebo-controlled international trial. Eur Heart J 1985;16:199-226.
70. Moss AJ, Hall WJ, Cannon DS, et al. Improved survival with an implanted defibrillator in patients with coronary artery disease at high risk for ventricular arrhythmia (MADIT). N Engl J Med 1996; 335:1933-40.
71. Muller JE, Morrison J, Stone PH, et al. Nifedipine therapy for patients with threatened and acute myocardial infarction: a randomized, double blind, placebo controlled comparison. Circulation 1984;69:740-7.
72. National Heart, Lung, and Blood Institute. Morbidity and mortality: chart-book on cardiovascular, lung, and blood diseases. Bethesda, Maryland: US Department of Health and Human Services, Public Health Service, National Institute of Health, 1992.
73. Neri Serneri GG, Rovelli F, Gensini GF, et al. Effectiveness of low-dose heparin in prevention of myocardial reinfarction. Lancet 1987;1:937-42.
74. Ockene JK. Smoking intervention: a behavioral, educational and pharmacologic perspective. In: Ockene IS, Ockene JK, eds. Prevention of coronary heart disease. Boston: Little Brown & Co, 1992: 201-30.
75. Oldridge NB, Guyatt GH, Fisher ME, et al. Cardiac rehabilitation after myocardial infarction: combined experience of randomized clinical trials. JAMA 1988;260:945-50.
76. Ornish D, Brown SE, Scherwitz LW, et al. Can life style changes reverse coronary artery disease: the Lifestyle Heart Trial. Lancet 1990;336:129-33.
77. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial - the SAVE Investigators. N Engl J Med 1992;327:669-77.
78. Pfisterer M, Cox JL, Granger CB, et al. Atenolol use and clinical out-comes after thrombolysis for acute myocardial infarction: the GUSTO-I experience. J Am Coll Cardiol 1998;32:634-40.
79. Pitt B, Water D, Brown WW, et al. Aggressive lipid-lowering compared with angioplasty in stable coronary artery disease: Atorvastatin VErsus Revascularization Treatment (AVERT) Investigators. N Engl J Med 1999;341:70-6.
80. Rengo F, Carbonin P, Pahor M, et al. A controlled trial of verapamil in patients after acute myocardial infarction: results of the Calcium antagonist Reinfarction Italian Study (CRIS). Am J Cardiol 1996;77:365-9.
81. Report of the Sixty Plus Reinfarction Study Research Group. A double-blind trial to assess long-term anticoagulation therapy in elderly patients after myocardial infarction. Lancet 1980;2: 989-94.
82. Rigotti NA, Singer DE, Mulley AG, et al. Smoking cessation following admission to coronary care unit. J Gen Inter Med 1991;6:305-11.
83. Rimm EB, Stampfer MJ, Ascherio A, et al. Vitamin E consumption and the risk of coronary artery disease in men. N Engl J Med 1993:328:1450-6.
84. Roberts R, Rogers WJ, Mueller HS, et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction: results of the Thrombolysis In Myocardial Infarction (TIMI) II-B subgroup analysis. Circulation 1991; 83:422-37.
85. Rogers WJ, Bowlby U, Chandra NC, et al. Treatment of myocardial infarction in United States (1990 to 1993): observations from National Registry of Myocardial Infarction. Circulation 1994; 90: 2103-14.
86. Ronnevik PK, Gundersen T, Abrahamsen AM. Effect of smoking habits and timolol treatment on mortality and reinfarction in patients surviving acute myocardial infarction. Br Heart J 1985; 54:134-9.
87. Rosenberg L, Kaufman DW, Helmrich SP, et al. The risk of myocardial infarction after quitting smoking in men under 55 years of age. N Engl J Med 1985;313:1511-4.
88. Ruberman W, Weinblatt E, Goldberg JD, et al. Psychosocial influences on mortality after myocardial infarction. N Engl J Med 1984;311:552-9.
89. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410-8.
90. Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the ACC/AHA Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation 1999;100:1016-30.
91. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: the Cholesterol And Recurrent Events (CARE) Trial. N Engl J Med 1996;335:1001-9.
92. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary artery disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
93. Second Report of the Working Party on Anticoagulation Therapy in Coronary Thrombosis of the Medical Research Council: An assessment of long term anticoagulant therapy after cardiac infarction. Br Med J 1964;837-43.
94. Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990; 323:147-52.
95. SPRINT Study Group. Nifedipine in secondary prevention after myocardial infarction. Harefuah 1989;116:1-6.
96. Stanford JL, Weiss NS, Voight LF, et al. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 1995;274:137-42.
97. Stephens NG, Parsons A, Schofield PM, et al. Randomized controlled trial of vitamin E in patients with coronary artery disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996;347: 781-6.
98. Sullivan JM, El-Zeky F, Vander Zwaag R, et al. Effect on survival of estrogen replacement therapy after coronary bypass surgery. Am J Cardiol 1997;79:847-50.
99. Sullivan JM, Vander Zwaag R, Hughes JP, et al. Estrogen replacement and coronary artery disease. Effect of survival on postmenopausal women. Arch Intern Med 1990;150:2557-662.
100. Superko HR, Krauss RM. Coronary artery disease regression: Convincing evidence for the benefit of aggressive lipoprotein management. Circulation 1994;90:1056-69.
101. Swedberg K, Held P, Kjekshus J, et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992;327: 678-84.
102. Taylor SH, Silke B, Ebbutt A, et al. A long-term prevention study with oxprenolol in coronary heart disease. N Engl J Med 1982; 307:1293-301.
103. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-8.
104. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancer in male smokers. N Engl J Med 1994;330:1029-35.
105. The ASPECT Research Group. The effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 1994;343:499.
106. The Cardiac Arrhythmias Suppression Trial II Investigators. Effects of the antiarrhythmic moricizine on survival after acute myocardial infarction. N Engl J Med 1992;327:227-33.
107. The EPSIM Research Group. A controlled comparison of aspirin and oral anticoagulants in in prevention of death after myocardial infarction. N Engl J Med 1982;307:701-8.
108. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of Cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol. N Engl J Med 1998;339:1349-57.
109. The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality after myocardial infarction. N Engl J Med 1988;319:385-92.
110. The Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981;304:801-7.
111. The TRACE Study Group. A clinical trial of angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. The Trandolapril Cardiac Evaluation (TRACE) study. N Engl J Med 1995;333:1670-6.
112. TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: results of Thrombolysis in Myocardial Infarction trial (TIMI), Phase II. N Engl J Med 1989; 320:618-27.
113. Tsevat J, Duke D, Goldman L, et al. Cost-effectiveness of captopril therapy after myocardial infarction. J Am Coll Cardiol 1995; 26:914-9.
114. Veterans Administration Cooperative Study Group. Long term anticoagulant therapy after myocardial infarction. Final report of the Veterans Administration Cooperative Study. JAMA 1965; 193:929-34.
115. Waldo AL, Camm AJ, DeRuyter H, et al. Survival with oral d-sotalol in patients with left ventricular dysfunction after myocardial infarction: rationale, design, and methods (the SWORD trial). Am J Cardiol 1995;75:1023-7.
116. Watts GF, Lewis B, Brunt JNH, et al. Effects on coronary artery disease of lipid lowering diet, or diet plus cholestyramine, in St Thomas' Atherosclerosis Regression Study (STARS). Lancet 1992; 339:563-9.
117. Wilcox RG, Hampton JR, Banks DC, et al. TRial of Early Nifedipine Treatment in acute myocardial infarction (the TRENT study). Br Med J (Clin Res) 1986;293:1204-8.
118. Wong ND, Wilson PWF, Kannel WB. Serum cholesterol as a prognostic factor after myocardial infarction: the Framingham Study. Ann Intern Med 1991;115:687-93.
119. Wong SC, Greenberg H, Hager WD, et al. Effects of diltiazem on recurrent myocardial infarction in patients with non-Q wave myocardial infarction. J Am Coll Cardiol 1992;19:1241-5.
120. Yusuf S, Pepine CJ, Garces C, et al. Effects of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992;340:1173-8.
121. Yusuf S, Peto R, Lewis J, et al. Beta-blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985;27:335-71.
122. Yusuf S, Wittes J, Freidman L. Overview of results of randomized clinical trials in heart disease: treatment following myocardial infarction. JAMA 1988;260:2088-93.
123. Zarembski DG, Nolan PE, Slack MK, et al. Empiric long-term amiodarone prophylaxis following myocardial infarction: a meta-analysis. Arch Intern Med 1993:153:2661-7.